ID: MRFR/HC/7159-HCR | February 2021 | Region: Global | 118 pages
ACE Inhibitors Market is expected to reach around USD 7682.8 Million by 2025 and is expected to register a CAGR of 3.10% between 2019 and 2025.
ACE inhibitors are a common choice of medications used to control high blood pressure. Benazepril, captopril, enalapril, cilazapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril are some of the ACE inhibitors used for treating hypertension. The prescribing rate of different types of ACE inhibitors varies according to the country. For instance, in New Zealand, about 60% of the people taking angiotensin-converting enzyme (ACE) inhibitors are prescribed cilazapril, whereas, in the UK and Australia, cilazapril is less frequently used.
Various major pharmaceutical companies are developing innovative products that are also contributing to the growth in the market. For instance, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned to tackle hypertension and heart failure. It is the first ready to use Ace inhibitor in oral solution form. Moreover, increasing the risk of developing high blood pressure and cardiovascular disorders due to the changing lifestyle ensures the growth in the ACE inhibitors market.
By Dosage Form
By Distribution Channel
|Market Size||USD 7682.8 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors and Trends|
|Segments Covered||Drug, Application, Dosage Form, Distribution Channel and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Pfizer, AbbVie Inc., AstraZeneca Bausch Health Companies, Novartis AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Silvergate Pharmaceuticals|
|Key Market Opportunities||
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
ACE Inhibitors Market is projected to grow at approximately 3.10% CAGR during the assessment period (2019-2025).
ACE Inhibitors Market is estimated to reach a valuation of approx. USD 7682.8 MN by the end of 2025
Rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, are major tailwinds pushing the growth of the global ACE inhibitors market.
North America holds the largest share in the Global ACE Inhibitors Market, followed by Europe and the Asia Pacific, respectively.
Par Pharmaceutical Companies, Inc. (US), Merck & Co., Inc.(US), Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd.(Israel), UCB, Inc. (Belgium), AstraZeneca (UK), AbbVie Inc.(US), Novartis AG (Switzerland), Pfizer, Inc.(US), Bausch Health Companies Inc.(Canada), and Silvergate Pharmaceuticals, Inc. (US), are some of the top players operating in the Global ACE Inhibitors Market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.